Nat Genet:老年人Y染色体比例或影响患癌风险

2014-07-01 佚名 手牵手博客站

《自然—遗传学》上的一项研究报告了男性老年人血液细胞中Y染色体的自然丧失与癌症高发率之间的联系。这项发现认为,针对Y染色体的血液检测或可作为一种预测癌症风险的工具。相比女性而言,男性在非性别特异性癌症的患病风险更高,但是原因一直未明。Lars Forsberg等人对超过1600名瑞典男性老年人的血液进行了DNA检测,来查找可能的遗传因素。随着男性年龄增长,血液细胞中的Y染色体的比例是正常的,但是研

《自然—遗传学》上的一项研究报告了男性老年人血液细胞中Y染色体的自然丧失与癌症高发率之间的联系。这项发现认为,针对Y染色体的血液检测或可作为一种预测癌症风险的工具。

相比女性而言,男性在非性别特异性癌症的患病风险更高,但是原因一直未明。Lars Forsberg等人对超过1600名瑞典男性老年人的血液进行了DNA检测,来查找可能的遗传因素。

随着男性年龄增长,血液细胞中的Y染色体的比例是正常的,但是研究人员发现,Y染色体比例更高的男性患癌风险增加,且平均寿命要比Y染色体比例低的男性少5.5年。之前,研究人员通过对另一组稍年轻的男性进行检测验证了该结论。

原始出处:


Forsberg LA1, Rasi C1, Malmqvist N2, Davies H1, Pasupulati S1, Pakalapati G1, Sandgren J3, de Ståhl TD3, Zaghlool A1, Giedraitis V4, Lannfelt L4, Score J5, Cross NC5, Absher D6, Janson ET7, Lindgren CM8, Morris AP9, Ingelsson E10, Lind L7, Dumanski JP1.Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer.Nat Genet. 2014 Jun;46(6):624-8. doi: 10.1038/ng.2966. Epub 2014 Apr 28.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061437, encodeId=e3c2206143e69, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 24 00:26:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048597, encodeId=21a4204859e97, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 03 18:26:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685949, encodeId=7e4016859491b, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 08 02:26:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733694, encodeId=aa201e336946a, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Aug 30 12:26:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880145, encodeId=90371880145d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 28 17:26:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331594, encodeId=496013315948b, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413425, encodeId=6da614134259a, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538838, encodeId=207c1538838e8, content=<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18991, encryptionId=9f5a189918d, topicName=Y染色体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc213064778, createdName=周虎, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601339, encodeId=89611601339cc, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061437, encodeId=e3c2206143e69, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 24 00:26:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048597, encodeId=21a4204859e97, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 03 18:26:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685949, encodeId=7e4016859491b, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 08 02:26:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733694, encodeId=aa201e336946a, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Aug 30 12:26:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880145, encodeId=90371880145d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 28 17:26:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331594, encodeId=496013315948b, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413425, encodeId=6da614134259a, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538838, encodeId=207c1538838e8, content=<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18991, encryptionId=9f5a189918d, topicName=Y染色体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc213064778, createdName=周虎, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601339, encodeId=89611601339cc, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=)]
    2014-11-03 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061437, encodeId=e3c2206143e69, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 24 00:26:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048597, encodeId=21a4204859e97, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 03 18:26:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685949, encodeId=7e4016859491b, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 08 02:26:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733694, encodeId=aa201e336946a, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Aug 30 12:26:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880145, encodeId=90371880145d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 28 17:26:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331594, encodeId=496013315948b, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413425, encodeId=6da614134259a, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538838, encodeId=207c1538838e8, content=<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18991, encryptionId=9f5a189918d, topicName=Y染色体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc213064778, createdName=周虎, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601339, encodeId=89611601339cc, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2061437, encodeId=e3c2206143e69, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 24 00:26:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048597, encodeId=21a4204859e97, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 03 18:26:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685949, encodeId=7e4016859491b, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 08 02:26:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733694, encodeId=aa201e336946a, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Aug 30 12:26:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880145, encodeId=90371880145d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 28 17:26:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331594, encodeId=496013315948b, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413425, encodeId=6da614134259a, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538838, encodeId=207c1538838e8, content=<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18991, encryptionId=9f5a189918d, topicName=Y染色体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc213064778, createdName=周虎, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601339, encodeId=89611601339cc, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=)]
    2014-08-30 canlab
  5. [GetPortalCommentsPageByObjectIdResponse(id=2061437, encodeId=e3c2206143e69, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 24 00:26:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048597, encodeId=21a4204859e97, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 03 18:26:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685949, encodeId=7e4016859491b, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 08 02:26:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733694, encodeId=aa201e336946a, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Aug 30 12:26:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880145, encodeId=90371880145d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 28 17:26:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331594, encodeId=496013315948b, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413425, encodeId=6da614134259a, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538838, encodeId=207c1538838e8, content=<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18991, encryptionId=9f5a189918d, topicName=Y染色体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc213064778, createdName=周虎, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601339, encodeId=89611601339cc, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=)]
    2015-03-28 liye789132251
  6. [GetPortalCommentsPageByObjectIdResponse(id=2061437, encodeId=e3c2206143e69, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 24 00:26:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048597, encodeId=21a4204859e97, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 03 18:26:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685949, encodeId=7e4016859491b, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 08 02:26:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733694, encodeId=aa201e336946a, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Aug 30 12:26:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880145, encodeId=90371880145d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 28 17:26:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331594, encodeId=496013315948b, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413425, encodeId=6da614134259a, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538838, encodeId=207c1538838e8, content=<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18991, encryptionId=9f5a189918d, topicName=Y染色体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc213064778, createdName=周虎, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601339, encodeId=89611601339cc, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2061437, encodeId=e3c2206143e69, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 24 00:26:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048597, encodeId=21a4204859e97, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 03 18:26:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685949, encodeId=7e4016859491b, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 08 02:26:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733694, encodeId=aa201e336946a, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Aug 30 12:26:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880145, encodeId=90371880145d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 28 17:26:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331594, encodeId=496013315948b, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413425, encodeId=6da614134259a, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538838, encodeId=207c1538838e8, content=<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18991, encryptionId=9f5a189918d, topicName=Y染色体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc213064778, createdName=周虎, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601339, encodeId=89611601339cc, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2061437, encodeId=e3c2206143e69, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 24 00:26:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048597, encodeId=21a4204859e97, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 03 18:26:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685949, encodeId=7e4016859491b, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 08 02:26:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733694, encodeId=aa201e336946a, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Aug 30 12:26:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880145, encodeId=90371880145d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 28 17:26:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331594, encodeId=496013315948b, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413425, encodeId=6da614134259a, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538838, encodeId=207c1538838e8, content=<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18991, encryptionId=9f5a189918d, topicName=Y染色体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc213064778, createdName=周虎, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601339, encodeId=89611601339cc, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=)]
    2014-07-03 周虎
  9. [GetPortalCommentsPageByObjectIdResponse(id=2061437, encodeId=e3c2206143e69, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 24 00:26:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048597, encodeId=21a4204859e97, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 03 18:26:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685949, encodeId=7e4016859491b, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 08 02:26:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733694, encodeId=aa201e336946a, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Aug 30 12:26:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880145, encodeId=90371880145d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 28 17:26:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331594, encodeId=496013315948b, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413425, encodeId=6da614134259a, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538838, encodeId=207c1538838e8, content=<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18991, encryptionId=9f5a189918d, topicName=Y染色体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc213064778, createdName=周虎, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601339, encodeId=89611601339cc, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Thu Jul 03 00:26:00 CST 2014, time=2014-07-03, status=1, ipAttribution=)]
    2014-07-03 lq0307

相关资讯

如果寿命够长,每个人都会得癌症?

昨天读了MelGreaves的一篇随笔(NatureReviewsCancer.2014,14,209-210.),文中称如果人类的寿命够长(90岁?),三分之一的人会确诊为癌症,我们所有人都会出现隐形癌症(covertcancer)。隐形癌症可以理解为亚癌症、癌前病变、检测不到的癌症,但从理论上来说,如果技术更先进,还是能够检测到的。 隐形癌症最主要的证据来自尸体解剖,一个经典的例子是前列腺

Lancet:石远凯谈糖尿病与癌症的错综关系

在全球范围内糖尿病和癌症是两种常见病,而且两者的患病率都呈快速增加的趋势。国际糖尿病联合会(IDF)统计2013年全球有3亿8200万例糖尿病患者,并预计到2035年,全球糖尿病患者将达到5亿9200万例,且其中80%病例将发生在中低收入国家。仅在中国,就有大约1亿1400万例成年人患有糖尿病,而且,其中大多数病了还未被确诊。 2012年全球有1400万癌症患者,WHO预计到2032年全球癌症患

ASCO 2014:ASCO大学癌症基因组项目

在过去的十年间,ASCO推出了多项癌症基因组举措,丰富了该领域的快速发展。这些举措促使了一些教育产品和政策建议的诞生,完善了癌症患者及其遗传高风险家属可用的预防性和治疗性的建议和方案。虽然这些举措带来了第一级和第二级家族史的文档备案的极大改进,但研究表明完整家族史的文档备案率以及对这些数据的解读情况仍还不理想。 ASCO">ASCO大学癌症基因组项目 为了满足这一需要,ASC

ASCO 2014:肥胖可能会影响癌症患者的结果

科学家们知道肥胖者患癌症的风险会增加。但一项新的研究表明肥胖同样会增加某些患者的癌症复发几率,以及这类患者死于癌症的几率。这项研究已在美国临床癌症学会2014年度会议前发布。研究人员在70种早期乳腺癌实验中观察80000名患者,分析他们身体质量指数,雌性激素受体,更年期状态,癌症复发以及预后情况。他们把10年期间里BMI稍高(高于30)的女人跟指数正常(20-25)的女人作对比,发现患乳腺癌且肥胖

Cell Reports:p53与ARF突变癌症患者可受益于JAM抑制剂

最近一项新研究证实,一些侵略性癌症患者可从一类用于治疗类风湿关节炎的抗炎药中受益。通过研究三阴性乳腺癌,华盛顿大学医学院研究人员发现一些侵略性肿瘤依赖于一种驱动炎症的抗病毒途径。 这个特殊抗病毒途径激活的肿瘤总是有不正常形式的p53与ARF蛋白,p53与ARF蛋白是由高度变异的两个基因(p53与ARF)编码。研究人员发现两个基因能相互“补偿”。如果两者都发生突变,形成的肿瘤比只有一个基因突变形成

ASCO 2014:3大癌症生存指南

为解决影响成人型癌症幸存者长期临床管理的一些临床问题,ASCO">ASCO连续制定了三个癌症幸存者指南,这些指南主要针对的问题是多种类型癌症幸存者都常见的一些症状包括抑郁、焦虑、疲劳和神经病变。 随着癌症幸存者人群的空前增多,人们对可帮助相关各方确定癌症后管理的具体策略的需求也日趋增加。 “患者、肿瘤学家和公众共同推动了人们对幸存者的兴趣增加,”癌症幸存者委员会主席、医学博士Kevin